
Personalised cancer vaccine cuts skin cancer recurrence risk by 42%: What this means for patients
The story in brief
A personalized cancer vaccine, intismeran, reduced skin cancer recurrence risk by 42% in a trial, with 82.2% of patients remaining recurrence-free after two years. The treatment targets high-risk melanoma patients post-surgery and faces regulatory review. Common side effects include fever and fatigue, while affordability and infrastructure remain key challenges.